-
ICD-10-CM Codes
›
-
E00-E89
›
-
E70-E88
›
-
E88-
›
-
2023 ICD-10-CM Diagnosis Code E88.3
2023 ICD-10-CM Diagnosis Code E88.3
Tumor lysis syndrome
2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
- E88.3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2023 edition of ICD-10-CM E88.3 became effective on October 1, 2022.
- This is the American ICD-10-CM version of E88.3 - other international versions of ICD-10 E88.3 may differ.
Applicable To- Tumor lysis syndrome (spontaneous)
- Tumor lysis syndrome following antineoplastic drug chemotherapy
Use AdditionalUse Additional Help
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions the ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation. In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere." Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code. "In diseases classified elsewhere" codes are never permitted to be used as first listed or principle diagnosis codes. They must be used in conjunction with an underlying condition code and they must be listed following the underlying condition.
The following code(s) above
E88.3 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to
E88.3:
- E00-E89
2023 ICD-10-CM Range E00-E89
Endocrine, nutritional and metabolic diseasesNote- All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Type 1 Excludes- transitory endocrine and metabolic disorders specific to newborn (P70-P74)
- E70-E88
2023 ICD-10-CM Range E70-E88
Metabolic disordersType 1 Excludes- androgen insensitivity syndrome (E34.5-)
- congenital adrenal hyperplasia (E25.0)
- hemolytic anemias attributable to enzyme disorders (D55.-)
- Marfan's syndrome (Q87.4)
- 5-alpha-reductase deficiency (E29.1)
Type 2 Excludes- Ehlers-Danlos syndromes (Q79.6-)
- E88
ICD-10-CM Diagnosis Code E88
Other and unspecified metabolic disorders
2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
Type 1 Excludes- histiocytosis X (chronic) (C96.6)
Use Additional- codes for associated conditions
- A condition of metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Tumor lysis syndrome typically occurs in aggressive, rapidly proliferating lymphoproliferative disorders. Burkitt lymphoma and t cell acute lymphoblastic leukemia are commonly associated with this syndrome. Metabolic abnormalities include hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia and may result in renal failure, multiple organ failure, and death.
- A condition that can occur after treatment of a fast-growing cancer, especially certain leukemias and lymphomas (cancers of the blood). As tumor cells die, they break apart and release their contents into the blood. This causes a change in certain chemicals in the blood, which may cause damage to organs, including the kidneys, heart, and liver.
- A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.
- A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
ICD-10-CM E88.3 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):
- 673 Other kidney and urinary tract procedures with mcc
- 674 Other kidney and urinary tract procedures with cc
- 675 Other kidney and urinary tract procedures without cc/mcc
- 682 Renal failure with mcc
- 683 Renal failure with cc
- 684 Renal failure without cc/mcc
- 791 Prematurity with major problems
- 793 Full term neonate with major problems
Convert E88.3 to ICD-9-CM
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
- Syndrome - see also Disease
- tumor lysis E88.3 (following antineoplastic chemotherapy) (spontaneous)
- Tumor lysis syndrome E88.3 (following antineoplastic chemotherapy) (spontaneous)
ICD-10-CM Codes Adjacent To E88.3
E87.71 Transfusion associated circulatory overload
E87.8 Other disorders of electrolyte and fluid balance, not elsewhere classified
E88 Other and unspecified metabolic disorders
E88.0 Disorders of plasma-protein metabolism, not elsewhere classified
E88.01 Alpha-1-antitrypsin deficiency
E88.09 Other disorders of plasma-protein metabolism, not elsewhere classified
E88.1 Lipodystrophy, not elsewhere classified
E88.2 Lipomatosis, not elsewhere classified
E88.3
Tumor lysis syndrome
E88.4 Mitochondrial metabolism disorders
E88.40 Mitochondrial metabolism disorder, unspecified
E88.49 Other mitochondrial metabolism disorders
E88.8 Other specified metabolic disorders
E88.89 Other specified metabolic disorders
E88.9 Metabolic disorder, unspecified
E89 Postprocedural endocrine and metabolic complications and disorders, not elsewhere classified
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.
